US · SLGL
Sol-Gel Technologies Ltd.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Ness Ziona 7403650
- Website
- sol-gel.com
Price · as of 2024-12-31
$75.61
Market cap 255.4M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $98.52 | +30.3% |
| Intrinsic Value(DCF) | $27.12 | -64.13% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $111.20 | ||||
| 2018 | $71.29 | $51.67 | $1.67 | $0.00 | $29.82 |
| 2019 | $94.70 | $2,719.60 | $186.55 | $0.00 | $0.00 |
| 2020 | $125.00 | $74.99 | $10.11 | $0.00 | $66.15 |
| 2021 | $75.50 | $111.56 | $1,643,040.30 | $3.11 | $35.41 |
| 2022 | $36.50 | $67.55 | $34.38 | $0.00 | $48.82 |
| 2023 | $11.00 | $26.30 | $1.34 | $0.00 | $49.53 |
| 2024 | $5.70 | $98.52 | $4,094.44 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Sol-Gel Technologies Ltd.'s (SLGL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $98.52
- Current price
- $75.61
- AI upside
- +30.3%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$27.12
-64.13% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SLGL | Sol-Gel Technologies Ltd. | $75.61 | 255.4M | +30% | -64% | — | — | -15.01 | 5.50 | 13.76 | -13.16 | — | 5.50 | 97.98% | -104.13% | -91.70% | -31.35% | -281.59% | -26.08% | 0.05 | — | 5.92 | 5.21 | 1.76 | -6238.00% | 64247.00% | -2224.00% | -8.75% | -2.63 | -325.58% | 0.00% | 0.00% | 7.76% | -11.33 | -9.80 | 11.80 | 4.69 |
| ANEB | Anebulo Pharmaceuticals, … | $0.36 | 14.68M | — | — | — | — | -9.49 | 6.90 | — | -8.50 | — | 6.90 | 0.00% | — | — | -109.69% | -2464.82% | -104.63% | 0.00 | -24.14 | 53.36 | 52.20 | 1.44 | -2188.00% | — | -2152.00% | -7.89% | -28.32 | -1696.85% | 0.00% | 0.00% | 10.60% | -7.47 | -10.85 | — | 89.17 |
| CLNN | Clene Inc. | $5.23 | 48.62M | +633% | -65% | — | +3,976% | -0.81 | -3.60 | 93.13 | -1.20 | — | -3.60 | 79.53% | -9676.32% | -11520.47% | -1738.36% | -637.51% | -98.90% | -2.35 | -8.14 | 1.57 | 1.22 | -0.26 | -3987.00% | -4771.00% | -3003.00% | -67.00% | -2.07 | -411.12% | 0.00% | 0.00% | 0.00% | -1.22 | -1.90 | 118.53 | -17.65 |
| COYA | Coya Therapeutics, Inc. | $4.96 | 82.41M | +515% | -78% | — | +508% | -7.05 | 2.65 | 29.50 | -3.87 | -29.29 | 2.65 | -233.86% | -485.35% | -418.70% | -39.57% | -774.97% | -34.76% | 0.00 | — | 11.59 | 10.22 | 2.23 | 2405.00% | -4079.00% | -804.00% | -9.81% | -2.69 | -484.62% | 0.00% | 0.00% | 5.45% | -3.86 | -6.46 | 18.71 | 11.79 |
| MGNX | MacroGenics, Inc. | $1.99 | 125.88M | +1,648% | -54% | — | — | -2.12 | 1.22 | 0.96 | 0.38 | -0.35 | 1.22 | 91.71% | -74.54% | -45.14% | -49.85% | 242.04% | -23.91% | 0.32 | -99.17 | 3.92 | 3.71 | 2.53 | 61333.00% | 15937.00% | -987.00% | -50.71% | -1.23 | 157.77% | 0.00% | 0.00% | 55.15% | 0.20 | 0.31 | -0.15 | -5.76 |
| OKYO | OKYO Pharma Limited | $1.71 | 69.35M | — | — | — | — | -9.41 | -13.52 | — | -10.37 | -0.05 | -13.52 | 0.00% | — | — | 139.47% | 61.45% | -305.45% | 0.00 | -8.14 | 0.40 | 0.37 | 0.22 | 1990000.00% | — | -8091.00% | -2.42% | -0.20 | 26.23% | 0.00% | 0.00% | 0.98% | -10.22 | -40.54 | — | -57.84 |
| ORMP | Oramed Pharmaceuticals In… | $3.42 | 136.08M | +1,195% | — | — | — | -5.13 | 0.67 | — | 2.94 | — | 0.67 | 0.00% | — | — | -12.29% | -43.99% | -10.14% | 0.00 | -14.98 | 25.19 | 24.97 | 3.63 | -43571.00% | -10000.00% | -2009.00% | -8.62% | -1.48 | -29.02% | 0.00% | 0.00% | 101.31% | 3.42 | 5.19 | — | 5.11 |
| OVID | Ovid Therapeutics Inc. | $1.63 | 116.08M | +1,596% | -87% | — | — | -1.39 | 0.54 | 65.14 | 0.03 | — | 0.54 | 100.00% | -10933.75% | -4670.14% | -33.88% | -444.08% | -22.38% | 0.22 | — | 5.32 | 5.04 | 0.20 | -5000.00% | 4439.00% | 2201.00% | -151.96% | -5.32 | -402.05% | 0.00% | 0.00% | 1.37% | 0.02 | 0.03 | -2.56 | -5.32 |
| PLRX | Pliant Therapeutics, Inc. | $1.30 | 79.88M | +1,747% | — | — | — | -0.47 | 0.32 | — | 0.96 | -1.78 | 0.32 | 0.00% | — | — | -54.09% | 61060.16% | -46.27% | 0.20 | -75.52 | 10.91 | 10.78 | 0.05 | 2618.00% | -10000.00% | 3587.00% | -162.48% | -4.68 | 42607.22% | 0.00% | 0.00% | 0.00% | 0.86 | 1.24 | — | -2.77 |
| TLSA | Tiziana Life Sciences Ltd | $1.45 | 86.17M | — | — | — | — | -9.51 | 22.90 | — | -5.21 | — | 22.90 | 0.00% | — | — | -200.16% | -455.01% | -80.79% | 0.03 | -2632.33 | 1.02 | 1.01 | 0.22 | -3529.00% | — | -9006.00% | -1.37% | -0.17 | -50.21% | 0.00% | 0.00% | 2.98% | -5.48 | -70.08 | — | -15.21 |
| ZNTL | Zentalis Pharmaceuticals,… | $2.39 | 172.68M | — | -34% | — | — | -0.78 | 0.38 | 1.92 | 1.07 | — | 0.38 | 100.00% | -283.57% | -245.96% | -42.83% | -4301.81% | -33.43% | 0.13 | — | 7.32 | 7.13 | -0.05 | -4787.00% | — | -1791.00% | -132.25% | -3.24 | -3849.27% | 0.00% | 0.00% | 6.95% | 1.04 | 1.16 | -2.95 | -2.98 |
About Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
- CEO
- Moshe Arkin
- Employees
- 34
- Beta
- 1.39
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($27.12 ÷ $75.61) − 1 = -64.13% (DCF, example).